A phase II randomized study of neoadjuvant pembrolizumab (P) alone or in combination with vidutolimod (V) in high-risk resectable melanoma: ECOG-ACRIN EA6194.

Overview of attention for article published in Journal of Clinical Oncology, June 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

news: 1 news outlet
twitter: 4 X users

bluesky: 1 Bluesky user

So far, Altmetric has seen 2 news stories from 1 outlets.

Neoadjuvant Vidutolimod Plus Pembrolizumab Displays High pCR Rates in Resectable Melanoma

OncLive, 14 Aug 2025

Resectable Melanoma | Image credit: © Artur - stock.adobe.com Neoadjuvant vidutolimod in combination with pembrolizumab (Keytruda…

Neoadjuvant Vidutolimod Plus Pembrolizumab Elicits Responses and Is Safe in Stage III Melanoma

OncLive, 25 Jun 2025

Ahmad Tarhini, MD, PhD The neoadjuvant combination of pembrolizumab (Keytruda) with the TLR9 agonist vidutolimod (formerly CMP-00…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.